Efficacy and safety of YAG laser vitreolysis for symptomatic posterior vitreous detachment

Harbin Aier Eye Hospital0 个研究点目标入组 306 人开始时间: 2022年10月13日最近更新: 2022年11月28日

试验速览

暂无简介。

•Current inclusion criteria as of 14/11/2022:
•1. Symptomatic vitreous opacities owing to complete PVD (Weiss ring), symptoms for at least 3 months
•2. No sensation of flashing for at least 2 weeks
•3. Clear optical media
•4. The distance between floaters and retina or lens was over 3mm (measured by B-scan ultrasound)
•5. The 10-point visual disturbance score of at least 4
•6. Ability to undertake YAG laser procedure
•7. Acceptance of related risks
•Previous inclusion criteria:
•1. Symptomatic vitreous opacities owing to complete PVD (Weiss ring), symptoms for at least 3 months
•2. Clear optical media
•3. The distance between floaters and retina or lens was over 3mm (measured by B-scan ultrasound)
•4. The 10-point visual disturbance score at least 4
•5. Ability to undertake YAG laser procedure
•6. Acceptance of related risks

•Current exclusion criteria as of 11/11/2022:
•1. Snellen BCVA was worse than 20/50
•2. Patients with a history of glaucoma, severe cataract, vitreous hemorrhage, retinal disease, macular disease.
•Previous exclusion criteria as of 18/10/2022:
•1. Snellen BCVA was worse than 20/50
•2. Less than 50% of the Weiss ring was ablated after one treatment (objective changes were evaluated by the surgeon who performed the YAG laser vitreolysis); patients with a history of glaucoma, severe cataract, vitreous hemorrhage, retinal disease, macular disease.
•Previous exclusion criteria:
•1. Snellen BCVA was worse than 20/50
•2. Eyes with intraocular lens (IOL)
•3. Less than 50% of the Weiss ring was ablated after one treatment (objective changes were evaluated by the surgeon who performed the YAG laser vitreolysis); patients with a history of glaucoma, severe cataract, vitreous hemorrhage, retinal disease, macular disease.

发起方

Harbin Aier Eye Hospital